Researchers hope to deliver a female-specific treatment approach for a condition that has been overlooked for generations.
A team led by UNSW Sydney has secured support through Wellcome Leap’s VISIBLE, opens in a new window program, a global research initiative investing more than $75 million ($US55 million) in women’s cardiovascular health.
Associate Professor Erin Howden from UNSW Medicine & Health will lead the RESTORE trial, which aims to deliver a female-specific treatment approach for coronary microvascular dysfunction (CMD), often referred to as invisible heart disease.
Powered by the strengths of our Member organisations

